Select region
Submit

Subscribe to our news feed

Subscribe

A question?

6/26/2024
Continuous ways to improve and innovate

Peta Ryan, Principal Analytical Development Chemist at Getinge, shares insights into her dynamic role at the Getinge’s Center for Excellence Advanced Materials Science Laboratory in Merrimack, U.S., where innovation and safety go hand in hand.

6/14/2024
Father and son duo share a quarter-century journey at Getinge

In the heart of Getinge’s Merrimack production site in New Hampshire, a beautiful story unfolds where Jason and Frank Smith, a dedicated father and son, celebrate 25 years of collaboration. Their journey in advancing medtech is also deeply personal, tied to the very devices that help saves lives, including their own.

6/12/2024
Getinge receives U.S. FDA 510(k) clearance for Talis +ACG Clinical Decision Support software, pioneering quality of high-acuity care in US and EU

Getinge has been granted U.S. FDA 510(k) clearance for its innovative clinical decision support software Talis +ACG (Advanced Clinical Guidance), steering in a new era of improving quality of care through promoting compliance with care protocols directly at the bedside in high acuity care environments. 

6/3/2024
Getinge Announces U.S. Launch of XEN Cleaning Chemistries to Enhance Safety and Efficiency in Sterile Processing Departments

Today Getinge announced the launch of XEN, a new and improved range of cleaning chemistries designed to optimize equipment performance, extend the lifespan of surgical instruments, and improve safety and efficiency in sterile processing departments (SPDs) across the U.S.

5/21/2024
Getinge introduces DPTE-BetaBag® with material from renewable sources

Getinge demonstrates its commitment to sustainable innovations by launching a new version of the DPTE-BetaBag®, used in sterile transfer. A new beta section made with the majority of plastic from renewable sources reduces the carbon footprint of the bag without compromising its sterile transfer capabilities.

5/14/2024
Getinge's financial target 2024-2028: Adjusted EPS growth of above 12% on average

Getinge updates its financial target for adjusted EPS growth 2024-2028 to be above 12% on average. The target takes into account today’s decisions (see below) that follow from the letter that the U.S. Food and Drug Administration (FDA) sent to healthcare providers in the US on May 8th.

Press Contacts

Lars Mattsson

Interim EVP Brand & Communication
Phone: +46 10 335 0043

Caroline Örmgård

Head of Public & Media Relations
Phone: +46 10 335 0041

Newsroom2

Contact us online

Click below to fill in the appropriate form. We will be in touch shortly.

Are you looking for

Getinge Hybrid OR

Image Gallery

Diverse picture format made available for press article purpose 

Man and woman looking a something together

About us

All you need to know about Getinge a one glance

Cardiosave

Urgent Medical Device Correction

Voluntary Urgent Medical Device Field Correction for the CARDIOSAVE intra-aortic balloon pump (IABP)

Newsroom

Don't miss anything

Click on the icons and follow us!